Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

141. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. Full Text available with Trip Pro

Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. Aspirin and low-molecular-weight heparin are prescribed for women with unexplained recurrent miscarriage, with the goal of improving the rate of live births, but limited data from randomized, controlled trials are available to support the use of these drugs.In this randomized trial, we enrolled 364 women between the ages of 18 and 42 years who had a history of unexplained recurrent miscarriage and were attempting

2010 NEJM Controlled trial quality: predicted high

142. Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention (Abstract)

Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention Bivalirudin demonstrated similar efficacy but resulted in a lower rate of bleeding compared to unfractionated heparin (UFH) plus platelet glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention. It has not been clearly evaluated whether this can also be applied to patients with diabetes

2009 EvidenceUpdates Controlled trial quality: predicted high

143. Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism: A Meta-Analysis of the Randomized Controlled Trials

Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism: A Meta-Analysis of the Randomized Controlled Trials PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2009 PedsCCM Evidence-Based Journal Club

144. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial Full Text available with Trip Pro

Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial Sodium citrate has antibacterial and anticoagulant properties that are confined to the catheter when used as a catheter lock. Studies of its use as a catheter lock have suggested its efficacy in preventing infection and bleeding complications compared with sodium heparin.Open-label randomized controlled trial of 2 catheter locks to examine the hypothesis that sodium (...) citrate catheter locks will reduce catheter-related bacteremia and exit-site infection.232 consenting long-term hemodialysis patients in 4 satellite dialysis units to a large dialysis program with protocolized treatment and targets. All patients were using twin-catheter single-lumen Tesio-Caths (MedComp, Harleysville, PA).6 months' use of 46.7% sodium citrate (citrate) or 5% heparin (heparin) locked postdialysis in the dead space of the central venous catheter.Primary end point of catheter-related

2009 EvidenceUpdates Controlled trial quality: uncertain

145. Unfractionated Heparin Therapy in Infants and Children (Abstract)

Unfractionated Heparin Therapy in Infants and Children Unfractionated heparin is frequently used in tertiary pediatric centers for the prophylaxis and treatment of thromboembolic disease. Recent evidence suggests that the clinical outcomes of unfractionated heparin therapy in children are poor, as determined by target-range achievement and adverse-event rates. These reports of poor outcomes may be related to an age-dependent mechanism of action of unfractionated heparin. Furthermore, several (...) published studies have indicated that unfractionated heparin-monitoring assays currently in clinical use have significant limitations that likely affect the safety and efficacy of anticoagulant management. This review summarizes the growing body of evidence suggesting that pediatric-specific recommendations for unfractionated heparin therapy management are required to improve clinical outcomes related to this commonly prescribed medication.

2009 EvidenceUpdates

146. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study) (Abstract)

Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study) The primary aims of this study were to determine the effects of heparin on length of stay and change from baseline multiple organ dysfunction (MOD) score. Secondary objectives were to estimate the effects of heparin on 28-day all-cause mortality, and to determine the possible effect modification on 28-day all-cause mortality, in subgroups defined by site of infection and baseline values of Acute (...) Physiology and Chronic Health Evaluation II score, MOD score, and d-dimer.Randomized, double-masked, placebo-controlled, single-center clinical trial, testing low dose continuous infusion of unfractioned heparin (UFH) as complementary treatment for sepsis.Five hundred fifty bed University Hospital and referral center in Medellín, Columbia.Three hundred nineteen patients admitted at the emergency room with signs indicative of sepsis.Patients were randomly assigned to receive placebo or UFH (500 units/hour

2009 EvidenceUpdates Controlled trial quality: predicted high

147. Low Molecular Weight Heparin and Aspirin for Recurrent Pregnancy Loss: Results from the Randomized, Controlled HepASA Trial (Abstract)

Low Molecular Weight Heparin and Aspirin for Recurrent Pregnancy Loss: Results from the Randomized, Controlled HepASA Trial

2009 EvidenceUpdates

148. Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention Full Text available with Trip Pro

Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention The aim of this study was to identify a subset of patients at high risk of bleeding or myocardial infarction from a percutaneous coronary intervention and to investigate whether such high-risk subsets derive preferential benefit from heparin or bivalirudin.This study included 4570 patients with coronary artery disease enrolled in the Intracoronary Stenting (...) and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment trial and randomized to receive bivalirudin or heparin. Primary outcomes were in-hospital incidence of major bleeding and 30-day incidence of myocardial infarction. Major bleeding, myocardial infarction, and bleeding plus myocardial infarction occurred in 140, 204, and 34 patients, respectively. Older age, female sex, lower body weight, low cholesterol, multi-lesion intervention, complex lesions, and heparin therapy were independent correlates

2009 EvidenceUpdates Controlled trial quality: uncertain

149. Heparin-Bonded Central Venous Catheters Do Not Reduce Thrombosis in Infants With Congenital Heart Disease: A Blinded Randomized, Controlled Trial (Abstract)

Heparin-Bonded Central Venous Catheters Do Not Reduce Thrombosis in Infants With Congenital Heart Disease: A Blinded Randomized, Controlled Trial Infants with congenital heart disease who require central venous lines are at increased risk of thrombosis. Heparin-bonded catheters provide protection from thrombotic events in some children. However, heparin-bonded catheters may not be as effective in infants heparin-bonded catheters in such specific high-risk populations. The objective of this study was to assess the efficacy of heparin-bonded catheters for preventing thrombosis in infants aged

2009 EvidenceUpdates Controlled trial quality: predicted high

150. Low molecular weight heparin effective for prevention of venous thromboembolism in patients with lower-leg immobilisation

Low molecular weight heparin effective for prevention of venous thromboembolism in patients with lower-leg immobilisation PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Low molecular weight heparin effective for prevention of venous thromboembolism in patients with lower-leg immobilisation Clinical question How effective is low molecular weight heparin (LMWH) for prevention of venous (...) be used for both below-knee and above-knee casts or braces. Caveat The six studies each used a different LMWH. The total number of patients was insufficient to evaluate which LMWH to choose. Complications of major bleeding events were extremely rare (0.3%) and there were no reports of heparin-induced thrombocytopenia. Context Immobilisation of the lower limb with plaster casts or braces in adult patients is associated with DVT and pulmonary embolism. In order to prevent these complications, preventive

2009 Cochrane PEARLS

151. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials

Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

152. Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review

Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

153. Activated partial thromboplastin time monitoring in patients receiving unfractionated heparin for venous thromboembolism in relation to clinical outcomes

Activated partial thromboplastin time monitoring in patients receiving unfractionated heparin for venous thromboembolism in relation to clinical outcomes Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

154. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analyis of randomised trials

Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analyis of randomised trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

155. Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy

Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy Tillman J CRD summary The author concluded that regional citrate anticoagulation was associated with increased haemofilter circuit survival (...) time and lower risk of bleeding, compared with systemic heparin anticoagulation in continuous renal replacement therapy for patients with acute renal failure. The reliability of this conclusion is unclear, given restrictions in the search strategy, and failure to minimise errors and bias in the review process. Authors' objectives To compare systemic heparin and regional citrate anticoagulation in continuous renal replacement therapy for patients with acute renal failure. Searching The Cochrane

2009 DARE.

156. Adjunctive low molecular weight heparin during fibrinolytic therapy in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials

Adjunctive low molecular weight heparin during fibrinolytic therapy in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

157. Heparin-bonded polytetrafluoroethylene (PTFE) gore propaten vascular graft (W.L. Gore & Associates Inc.) for treatment of peripheral arterial disease

Heparin-bonded polytetrafluoroethylene (PTFE) gore propaten vascular graft (W.L. Gore & Associates Inc.) for treatment of peripheral arterial disease Heparin-bonded polytetrafluoroethylene (PTFE) gore propaten vascular graft (W.L. Gore & Associates Inc.) for treatment of peripheral arterial disease Heparin-bonded polytetrafluoroethylene (PTFE) gore propaten vascular graft (W.L. Gore & Associates Inc.) for treatment of peripheral arterial disease Record Status This is a bibliographic record (...) of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from Citation Heparin-bonded polytetrafluoroethylene (PTFE) gore propaten vascular graft (W.L. Gore & Associates Inc.) for treatment of peripheral arterial disease . Lansdale: HAYES, Inc.. 2009 Authors' objectives According to the American Heart Association, 8 to 12 million Americans have peripheral arterial disease (PAD), a disease in which blood flow

2009 Health Technology Assessment (HTA) Database.

158. Low molecular weight heparins: review of the comparative effectiveness for various indications

Low molecular weight heparins: review of the comparative effectiveness for various indications Low molecular weight heparins: review of the comparative effectiveness for various indications Low molecular weight heparins: review of the comparative effectiveness for various indications Hutton B, Nkansah E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Hutton B, Nkansah E. Low molecular weight heparins: review of the comparative effectiveness for various indications. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2009 Authors' conclusions There currently exists relatively little published data for head-to-head comparisons amongst the low molecular weight heparins tinzaparin (Innohep), enoxaparin (Lovenox), nadroparin (Fraxiparin), and dalteparin (Fragmin). No health technology assessment reports, systematic

2009 Health Technology Assessment (HTA) Database.

159. Portable compression device and low-molecular-weight heparin compared with low-molecular-weight heparin for thromboprophylaxis after total joint arthroplasty (Abstract)

Portable compression device and low-molecular-weight heparin compared with low-molecular-weight heparin for thromboprophylaxis after total joint arthroplasty This preliminary prospective study to determine the rate of deep venous thrombosis (DVT) examined 277 patients undergoing total knee or total hip arthroplasty (TKA or THA) who were randomized to use a portable, continuous enhanced circulation therapy (CECT) compression device and low-molecular-weight heparin (LMWH) or to receive LMWH alone

2009 EvidenceUpdates Controlled trial quality: uncertain

160. Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: a Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction

Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: a Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: a Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute (...) Myocardial Infarction Treatment - Thrombolysis in Myocardial Infarction (ExTRACT-TIMI) 25 trial Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: a Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis in Myocardial Infarction (ExTRACT-TIMI) 25 trial Welsh RC, Sauriol L, Zhang Z, Kolm P, Weintraub WS, Theroux P Record Status

2009 NHS Economic Evaluation Database.